New drug trial targets rare, aggressive cancer subtype

NCT ID NCT07162480

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial is testing a drug called puxitatug samrotecan (AZD8205) in 28 adults with an aggressive form of adenoid cystic carcinoma that has spread or come back. The study aims to see if the drug is safe and effective for this specific cancer subtype. Participants will receive the drug through an IV, and researchers will monitor for side effects and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: puxitatug samrotecan (AZD8205)
What this could lead to: If successful, this could provide a new treatment option for people with an aggressive form of adenoid cystic carcinoma that has spread or come back.
What could go wrong: This is a small, early-phase trial with only 28 participants, so results may not apply to everyone. The drug may cause side effects or not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoid cystic carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOID CYSTIC CARCINOMA

Contacts and locations

Locations

The University of Texas M. D. Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.